Literature DB >> 16652147

RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.

E Reed-Inderbitzin1, I Moreno-Miralles, S K Vanden-Eynden, J Xie, B Lutterbach, K L Durst-Goodwin, K S Luce, B J Irvin, M L Cleary, S J Brandt, S W Hiebert.   

Abstract

RUNX1 (AML1) is a gene that is frequently disrupted by chromosomal translocations in acute leukemia. Like its Drosophila homolog Runt, RUNX1 both activates and represses transcription. Both Runt and RUNX1 are required for gene silencing during development and a central domain of RUNX1, termed repression domain 2 (RD2), was defined as being required for transcriptional repression and for the silencing of CD4 during T-cell maturation in thymic organ cultures. Although transcriptional co-repressors are known to contact other repression domains in RUNX1, the factors that bind to RD2 had not been defined. Therefore, we tested whether RD2 contacts histone-modifying enzymes that may mediate both repression and gene silencing. We found that RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous Suv39h1 associates with a Runx1-regulated repression element in murine erythroleukemia cells. In addition, one of these SUV39H1-binding motifs is also sufficient for binding to histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-mediated transcriptional repression. The association between RUNX1, histone deacetylases and SUV39H1 provides a molecular mechanism for repression and possibly gene silencing mediated by RUNX1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652147     DOI: 10.1038/sj.onc.1209591

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Authors:  John Anto Pulikkan; Mahesh Hegde; Hafiz Mohd Ahmad; Houda Belaghzal; Anuradha Illendula; Jun Yu; Kelsey O'Hagan; Jianhong Ou; Carsten Muller-Tidow; Scot A Wolfe; Lihua Julie Zhu; Job Dekker; John Hackett Bushweller; Lucio Hernán Castilla
Journal:  Cell       Date:  2018-06-28       Impact factor: 41.582

2.  The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.

Authors:  Gang Huang; Xinghui Zhao; Lan Wang; Shannon Elf; Hao Xu; Xinyang Zhao; Goro Sashida; Yue Zhang; Yan Liu; Jennifer Lee; Silvia Menendez; Youyang Yang; Xiaomei Yan; Pu Zhang; Daniel G Tenen; Motomi Osato; James J-D Hsieh; Stephen D Nimer
Journal:  Blood       Date:  2011-10-19       Impact factor: 22.113

Review 3.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 4.  Sound of silence: the properties and functions of repressive Lys methyltransferases.

Authors:  Chiara Mozzetta; Ekaterina Boyarchuk; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Nat Rev Mol Cell Biol       Date:  2015-08       Impact factor: 94.444

Review 5.  Roles of repressive epigenetic machinery in lineage decision of T cells.

Authors:  Taku Naito; Ichiro Taniuchi
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

Review 6.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 7.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

Review 8.  Oncogene-induced senescence: an essential role for Runx.

Authors:  Anna Kilbey; Anne Terry; Ewan R Cameron; James C Neil
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

9.  The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.

Authors:  Ophélie Philipot; Véronique Joliot; Ouardia Ait-Mohamed; Céline Pellentz; Philippe Robin; Lauriane Fritsch; Slimane Ait-Si-Ali
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

10.  Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development.

Authors:  Indrani Rajan; Katerina V Savelieva; Gui-Lan Ye; Ching-Yun Wang; Murtaza M Malbari; Carl Friddle; Thomas H Lanthorn; Wandong Zhang
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.